AcadeMab Biomedical
Taiwan - Taipei CityBiotechnology
Focus: AcadeMab Biomedical is a Taiwan-based biotechnology company founded in 2020, specializing in antibody and mRNA drug development with a focus on gene therapy. The company is early-stage with minimal public revenue footprint and a nascent clinical pipeline.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Open Jobs
0
About AcadeMab Biomedical
AI assessmentNot HiringNo open roles listed right now. Follow AcadeMab Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from AcadeMab Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
LOE Approaching
Approved product with approaching loss of exclusivity; likely a legacy or licensed asset rather than core pipeline driver.
Products & Portfolio (1)
Help build intelligence for AcadeMab Biomedical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.